Dure geneesmiddelen * (extramuraal), de vergoeding in 2021
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|
| Rang 2021 |
ATC-code | |||||
| 1 | J06BA02 Immunoglobuline normaal intravasculair (Nanogam ®) | 53.696.200 | 61.820.000 | 67.401.800 | 72.223.300 | 74.051.500 |
| 2 | C10AX13 Evolocumab (Repatha ®) | 20.213.900 | 33.398.200 | 39.992.200 | 48.228.100 | 55.452.200 |
| 3 | L04AX07 Dimethylfumaraat (Tecfidera ®) | 26.212.400 | 36.651.100 | 48.682.500 | 51.172.100 | 51.623.100 |
| 4 | C10AX14 Alirocumab (Praluent ®) | 9.788.000 | 20.154.800 | 30.221.700 | 41.013.500 | 47.595.400 |
| 5 | N04BA02 Levodopa met decarboxylaseremmer (Sinemet ®) | 35.995.000 | 38.667.100 | 43.358.300 | 44.783.300 | 41.655.400 |
| 6 | R07AX30 Ivacaftor met lumacaftor (Orkambi ®) | 7.118.000 | 89.989.900 | 67.653.000 | 42.097.600 | 37.701.300 |
| 7 | R07AX02 Ivacaftor (Kalydeco ®) | 9.238.200 | 10.484.000 | 22.203.000 | 39.515.800 | 37.333.400 |
| 8 | C09DX04 Valsartan met sacubitril (Entresto ®) | 2.779.800 | 6.565.300 | 12.007.500 | 19.356.600 | 29.661.000 |
| 9 | J05AR20 Emtricitabine met tenofoviralafenamide en bictegravir (Biktarvy ®) | . | 866.360 | 15.884.800 | 24.907.900 | 28.354.500 |
| 10 | L04AD02 Tacrolimus (Prograft ®) | 29.571.600 | 31.591.500 | 33.212.600 | 33.051.800 | 27.787.300 |
| 11 | R07AX31 Ivacaftor met tezacaftor (Symkevi ®) | . | . | 12.106.600 | 31.613.500 | 27.141.400 |
| 12 | B03XA02 Darbepoetine alfa (Aranesp ®) | 24.154.600 | 26.005.200 | 28.509.400 | 29.549.500 | 26.654.000 |
| 13 | L04AA27 Fingolimod (Gilenya ®) | 24.380.400 | 27.140.800 | 27.466.100 | 25.303.800 | 25.242.300 |
| 14 | A09AA02 Multi-enzymen (lipase protease enz) (Creon ®) | 17.934.200 | 18.891.800 | 21.110.300 | 22.960.700 | 23.967.000 |
| 15 | J05AR18 Emtricitabine tenofovir alafenamide elvitegravir cobicista (Genvoya ®) | 26.084.400 | 33.761.900 | 31.923.000 | 27.966.100 | 23.644.000 |
| 16 | H01CB03 Lanreotide (Somatuline ®) | 18.775.100 | 20.823.000 | 23.342.800 | 25.068.200 | 22.373.200 |
| 17 | J05AR13 Lamivudine met abacavir en dolutegravir (Triumeq ®) | 32.075.500 | 35.245.200 | 32.866.400 | 27.020.500 | 20.891.900 |
| 18 | C02KX04 Macitentan (Opsumit ®) | 15.307.500 | 18.914.600 | 20.323.200 | 22.101.100 | 20.459.400 |
| 19 | L01EX09 Nintedanib (Ofev ®) | 7.704.100 | 9.377.100 | 10.458.000 | 11.985.900 | 17.350.900 |
| 20 | J06BA01 Immunoglobuline normaal extravasculair (Cuvitru ®) | 8.357.700 | 10.940.400 | 13.945.300 | 15.830.500 | 16.589.900 |
| 21 | L04AA31 Teriflunomide (Aubagio ®) | 10.976.800 | 12.681.800 | 14.052.400 | 15.093.400 | 15.718.800 |
| 22 | H01CB02 Octreotide (Sandostatine ®) | 23.379.500 | 23.427.100 | 22.726.900 | 21.123.500 | 15.067.200 |
| Totaal | 403.742.900 | 567.397.160 | 639.447.800 | 691.966.700 | 686.315.100 | |